Preliminary Thoughts on Evaluating Harm Reduction Claims Based on the Mass SAB Experience 2003 National Conference on Tobacco or Health David Burns MD.

Slides:



Advertisements
Similar presentations
Regulation of amounts of various constituents in cigarette smoke.
Advertisements

Causality Causality Hill’s Criteria Cross sectional studies.
Session 8b Decision Models -- Prof. Juran.
TRP Chapter Chapter 2.3 Environmental impacts and health risks.
1 Preliminary Information Concerning the Establishment of a List of Harmful and Potentially Harmful Tobacco Product Constituents Before the FDA Tobacco.
Emerging Tobacco Product Issues -- The New Kids in Town MDCH Tobacco Program September 2009.
Comparing Methods for the Real- Time Measurement of Secondhand Tobacco Smoke Particles Neil E. Klepeis Visiting Scholar, Stanford University, Department.
Chemical Carcinogens – workplace risk assessment and health surveillance Tiina Santonen Paide.
Paracelsus “The dose makes the poison ”. MSDS Environmental Hazards and Human Health Chapter 17.
Unit 14: Measures of Public Health Impact.
Menthol and Tobacco Regulation
ADDITIONAL TESTS Ignition Propensity Testing Toxicity Assays.
Information on tobacco packages could encourage and help tobacco users to stop using tobacco or find least possible harmful ways of use for those unable.
Chapter 10: Hypothesis Testing
Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine.
 2011 Johns Hopkins Bloomberg School of Public Health Regulation of Tobacco Products Mitch Zeller, JD Pinney Associates.
Greens MyLifeForceBalance.com These statements has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any.
Electronic cigarettes (e-cigarettes) are battery operated devices that resemble the appearance of a cigarette and produce a warm vapor when withdrawn from.
1 Questions to the Subcommittee 1.What criteria do you recommend to TPSAC for selecting the initial list of H/PH constituents?
Kenneth E. Warner University of Michigan University of Iowa November 15, 2002 Technology, Policy, and the Future of Nicotine Addiction.
Our Global Harm Reduction Programme TMA 2009 David O’Reilly, PhD Head of Public Health & Scientific Affairs © British-American Tobacco (Holdings) Limited.
Environmental Hazards, Risk, & Human Health. Leading Causes of Mortality.
Do Electronic Cigarettes Correlate with Cancer?
EPA’s cancer risk assessment guidelines: General overview Jim Cogliano, Ph.D. United States Environmental Protection Agency* Office of Research and Development.
Health and Safety Executive UK Approach to Risk Assessment of Genotoxic Carcinogens in the Occupational Setting Dr Susy Brescia Chemicals Regulation Directorate.
Committee on Carcinogenicity (COC) Approach to Risk Assessment of Genotoxic Carcinogens David H. Phillips* COC Chairman Descriptive vs. Quantitative.
 2007 Johns Hopkins Bloomberg School of Public Health Tobacco Control Surveillance Benjamin Apelberg, PhD, MHS Institute for Global Tobacco Control Johns.
The Effect of Product Characteristics on Perceptions of E-cigarettes among Canadians Christine Czoli, PhD Student May 28, 2014.
Le rôle de la réduction de dommages dans la lutte antitabac The role of harm reduction in tobacco control Lars M. Ramström Institute for Tobacco Studies.
 2011 Johns Hopkins Bloomberg School of Public Health Jonathan M. Samet, MD, MS Director, USC Institute for Global Health Professor and Flora L. Thornton.
 Is there a comparison? ◦ Are the groups really comparable?  Are the differences being reported real? ◦ Are they worth reporting? ◦ How much confidence.
Pattern and pace of change in social norms in Massachusetts Giulia Norton (Presented by Tandiwe Njobe) National Conference on Tobacco or Health November.
Lung Cancer Molecular Pathology of Cancer Boot Camp January 4, 2012 Jennifer Rider, ScD.
Chapter 15 APES Environmental Risks & Human Health.
Unit B1a 3.4 Smoking and Health Year 4N 29th November.
Lung Images Normal Lung Internal Comparison- Tar.
Successful Concepts Study Rationale Literature Review Study Design Rationale for Intervention Eligibility Criteria Endpoint Measurement Tools.
Mutations 3.29 Recall that mutation is a rare, random change in genetic material that can be inherited.   3.31 Understand that many mutations are harmful.
PARTICLE EMISSIONS FROM TYRE AND BRAKE WEAR OPEN QUESTIONS Sustainable Transport Unit Institute for Energy and Transport Joint Research Centre 8 January.
The Importance of Research in Tobacco Control Jeffrey Koplan, MD, MPH Emory Global Health Institute- China Tobacco Control Partnership.
MAIN TOXICITY TESTING. TESTING STRATEGIES A number of different types of data are used in order to establish the safety of chemical substances for use.
DNA, Mutations and Hazardous Waste. Prokaryote Cell.
Cutting tobacco’s death toll − an overview of different options Lars M. Ramström Institute for Tobacco Studies Stockholm, Sweden 5th Annual Conference.
Tobacco Use. What’s in Tobacco?  Tobacco contains many harmful chemicals.  It is a drug that speeds up your heart rate and affects the central nervous.
The Role of Harm Reduction in Tobacco control – An Update of Pros and Cons Lars M. Ramström Institute for Tobacco Studies Stockholm, Sweden 53rd International.
Objectives Know radiation and mutagenic chemicals increase the mutation rate and can cause genetic diseases and cancer. Application: Consequences of radiation.
Factors Affecting Youth Awareness of Anti-Tobacco Media Messages Komal Kochhar, M.B.B.S., M.H.A. Terrell W. Zollinger, Dr.P.H. Robert M. Saywell, Jr.,
Chapter 15.3 Risk Assessment 2002 WHO report: “Focusing on risks to health is the key to preventing disease and injury.” risk assessment—process of evaluating.
RISK DUE TO AIR POLLUTANTS
Department of Family Medicine Smoking Cessation Counselling By: Lucie Desjardins Bscn R.N Certified Smoking Cessation Counsellor from CAMH.
Wellness Chapter 20 Tobacco Lesson One The Health Risks of Tobacco Use.
11/6/03LSRO presentation Draft for discussion PM USA Mission Our goal is to be the most responsible, effective and respected developer, manufacturer and.
1 Harmful/Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Tobacco Product Constituents Subcommittee Meeting July 7, 2010 Corinne.
Responsible Officer, Volume 112 Monographs Programme
1 of of 23 What if… An industry markets a product as "safe", but it’s the leading cause of preventable death in the United States?
Caroline O. Cobb, Ph.D. VCU Psychology Department & Center for the Study of Tobacco Products Vaping & Students: Who’s Puffing What?
Strategies for regulation of cigarette emissions The WHO product regulatory approach Nigel Gray David Burns For TobReg Working Group 1 in Conjunction with.
Regulation of: - amounts of various constituents in cigarette smoke - information on packages regarding smoke constituents - smokefree tobacco products.
Department of Family Medicine
The Impact of Smoking Cessation on Real-World Prospective Memory
Tobacco Use.
Concepts of Fitness & Wellness 8e
Griffith Health Institute
Trends in use of electronic cigarettes in England
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
The Consortium for Environmental Risk Management, LLC
Risk, Toxicology, and Human Health
1.6 U.6 Mutagens, oncogenes and metastasis are involved in the development of primary and secondary tumours. Tumours are abnormal growth of tissue that.
ANalysis Of VAriance Lecture 1 Sections: 12.1 – 12.2
Presentation transcript:

Preliminary Thoughts on Evaluating Harm Reduction Claims Based on the Mass SAB Experience 2003 National Conference on Tobacco or Health David Burns MD

Preliminary Thoughts Framework of Measures Cigarette design features Cigarette design features Smoke chemistry Smoke chemistry Measures of toxicity Measures of toxicity Measures of exposure Measures of exposure Measures of Injury Measures of Injury Measures of outcome Measures of outcome

Preliminary Thoughts Harm Reduction Cascade  Design  Smoke composition  Toxicity  Exposure  Injury  Disease incidence  Disease incidence

Preliminary Thoughts We Need to Test both the product We need to evaluate toxicity for both the product and for the product as it is used by the smoker We need to evaluate toxicity for both the product and for the product as it is used by the smoker We cannot assume that the only difference between smokers who use different products is the product they use We cannot assume that the only difference between smokers who use different products is the product they use

Preliminary Thoughts Design Examples Easily verified, but may convey claims of harm reduction Filter vs filtered Filter vs filtered Menthol Menthol Nicotine free Nicotine free

Preliminary Thoughts Smoke Chemistry Reproducible test methods Reproducible test methods Large, potentially incomplete, list of toxic constituents Large, potentially incomplete, list of toxic constituents Generation conditions must match conditions of use to be meaningful for dose of exposure estimates Generation conditions must match conditions of use to be meaningful for dose of exposure estimates

Preliminary Thoughts Tests of Toxicity The chain of scientific logic and evidence must be complete to link the testing as it is used in evaluating cigarettes to the outcomes (e.g. carcinogenicity). The chain of scientific logic and evidence must be complete to link the testing as it is used in evaluating cigarettes to the outcomes (e.g. carcinogenicity). It is not enough to assume that the name of the testing (mutagenicity, genotoxicity, cytotoxicity) applies to cigarettes if the tests are used differently. It is not enough to assume that the name of the testing (mutagenicity, genotoxicity, cytotoxicity) applies to cigarettes if the tests are used differently.

Preliminary Thoughts Tests of Toxicity Matrix What does the test measure What does the test measure What is the protocol What is the protocol What is its reproducibility within and across laboratories What is its reproducibility within and across laboratories How big a difference in the test measure is necessary to be considered a real difference How big a difference in the test measure is necessary to be considered a real difference Do real differences in the test values correspond to other measures of exposure or toxicity Do real differences in the test values correspond to other measures of exposure or toxicity

Preliminary Thoughts Tests of Toxicity Matrix Have differences been validated as a measure of toxicity as the test is used Have differences been validated as a measure of toxicity as the test is used Has a change in the measure been shown to correspond to a change in toxicity in animals or humans Has a change in the measure been shown to correspond to a change in toxicity in animals or humans Has a change in the measure been shown to a change in disease rates Has a change in the measure been shown to a change in disease rates

Preliminary Thoughts Mutagenicity as Used By Tobacco Companies

Preliminary Thoughts Mutagenicity Measures specific point mutations—substitution, addition, or deletion of one or a few DNA base pairs Measures specific point mutations—substitution, addition, or deletion of one or a few DNA base pairs Normally used to screen for carcinogenicity as a positive or negative test, as opposed to a quantitative measure of mutagenic potential Normally used to screen for carcinogenicity as a positive or negative test, as opposed to a quantitative measure of mutagenic potential Cigarette smoke is not mutagenic with all strains tested Cigarette smoke is not mutagenic with all strains tested Mutations for a single strain are likely at a specific site and are likely influenced by individual carcinogens or groups of carcinogens Mutations for a single strain are likely at a specific site and are likely influenced by individual carcinogens or groups of carcinogens If there is an increase in the number of mutations per mg tar, does that mean that the tar is more carcinogenic or simply that it contains a more of one chemical that the bacteria is sensitive to? If there is an increase in the number of mutations per mg tar, does that mean that the tar is more carcinogenic or simply that it contains a more of one chemical that the bacteria is sensitive to? Is the slope of the mutagenicity a measure of toxicity or a measure of smoke chemistry Is the slope of the mutagenicity a measure of toxicity or a measure of smoke chemistry

Preliminary Thoughts Current Utility of Tests Smoke Chemistry – Design Smoke Chemistry – Design Mutagenicity – Design Mutagenicity – Design Cytotoxicity -Design Cytotoxicity -Design Inhalation – Design Inhalation – Design Skin Painting – Toxicity Skin Painting – Toxicity Cotinine and CO – Exposure Cotinine and CO – Exposure Others - Developmental Others - Developmental

Preliminary Thoughts Human Exposure Studies Cautions

Preliminary Thoughts California Tobacco Survey: Current Smoking Status Compared to Smoking Status 1 Year Ago Daily Smokers 1 Year Ago, 25 Years and Older The test of marginal homogeneity is significant (chi-squared = on 3 df, p < ). This suggests there is a slight downward trend in the intensity of smoking. Shift

Preliminary Thoughts Unanswered Questions on How We Measure Exposure Differences Do we need to express yield comparisons in mg’s per mg of nicotine? Do we need to express yield comparisons in mg’s per mg of nicotine? Do we need to express exposure measures per mg of cotinine? Do we need to express exposure measures per mg of cotinine? What do we do with those who quit or cut down in any comparison? What do we do with those who quit or cut down in any comparison? What else needs to be controlled? What else needs to be controlled?

Preliminary Thoughts SUMMARY Tests of smoke chemistry are not measures of exposure until we find a way to match machine measurements and actual smoking patterns, an achievable outcome. Tests of smoke chemistry are not measures of exposure until we find a way to match machine measurements and actual smoking patterns, an achievable outcome. Mutagenicity and cytotoxicity testing are screening tools and whether they can be used to assess relative toxicity is uncertain Mutagenicity and cytotoxicity testing are screening tools and whether they can be used to assess relative toxicity is uncertain Measures of exposure are available but we are uncertain how to appropriately compare human smokers who change brands Measures of exposure are available but we are uncertain how to appropriately compare human smokers who change brands